Is This Stock-Split Stock a Buy For 2023?

Is This Stock-Split Stock a Buy For 2023?

Over the past 10 months, several high-profile stock splits helped animate an already lively stock market. One of them was that of the medical device expert DexCom (NASDAQ: DXCM), which completed a 4-for-1 stock split in June. Of course, stock splits don't fundamentally change the prospects of the company, and DexCom's did little to jolt its stock performance in 2022.